<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Reprod</journal-id><journal-id journal-id-type="iso-abbrev">Hum. Reprod</journal-id><journal-id journal-id-type="publisher-id">humrep</journal-id><journal-title-group><journal-title>Human Reproduction (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0268-1161</issn><issn pub-type="epub">1460-2350</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28541398</article-id><article-id pub-id-type="pmc">5946864</article-id><article-id pub-id-type="doi">10.1093/humrep/dex208</article-id><article-id pub-id-type="publisher-id">dex208</article-id><article-categories><subj-group subj-group-type="heading"><subject>Corrigendum</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Humaidan</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="dex208af1">1</xref><xref ref-type="aff" rid="dex208af2">2</xref><xref ref-type="corresp" rid="dex208cor1"/><!--<email>peter.humaidan@midt.rm.dk</email>--></contrib><contrib contrib-type="author"><name><surname>Chin</surname><given-names>W.</given-names></name><xref ref-type="aff" rid="dex208af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rogoff</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="dex208af4">4</xref><xref ref-type="author-notes" rid="dex208fn1"/></contrib><contrib contrib-type="author"><name><surname>D'Hooghe</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="dex208af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Longobardi</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dex208af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hubbard</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dex208af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schertz</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dex208af4">4</xref><on-behalf-of>on behalf of the ESPART Study Investigators</on-behalf-of><xref ref-type="author-notes" rid="dex208fn2"/></contrib></contrib-group><aff id="dex208af1">
<label>1</label>
<addr-line>The Fertility Clinic, Skive Regional Hospital, Skive</addr-line>, <country>Denmark</country></aff><aff id="dex208af2">
<label>2</label>
<addr-line>Faculty of Health</addr-line>, <institution>Aarhus University</institution>, <addr-line>Aarhus</addr-line>, <country>Denmark</country></aff><aff id="dex208af3">
<label>3</label>
<addr-line>Global Biostatistics and Epidemiology, EMD Serono, Billerica, MA, USA, a business of Merck KGaA, Darmstadt</addr-line>, <country>Germany</country></aff><aff id="dex208af4">
<label>4</label>
<addr-line>Global Clinical Development, EMD Serono Research and Development Institute, Billerica, MA, USA, a business of Merck KGaA, Darmstadt</addr-line>, <country>Germany</country></aff><aff id="dex208af5">
<label>5</label>
<addr-line>Global Medical Affairs Fertility, Merck KGaA, Darmstadt</addr-line>, <country>Germany</country></aff><author-notes><corresp id="dex208cor1"><label>*</label>Correspondence address. The Fertility Clinic, Skive Regional Hospital, Faculty of Health, Aarhus University, Skive, Denmark. Tel: +<phone>45-23-81-59-91</phone>; E-mail: <email>peter.humaidan@midt.rm.dk</email></corresp><fn id="dex208fn1"><label>&#x02020;</label><p>Former employee of EMD Serono Research and Development Institute, a business of Merck KGaA, Darmstadt, Germany</p></fn><fn id="dex208fn2"><label>&#x02021;</label><p>ESPART Study Investigators are listed in the Acknowledgements of the original article.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-05-25"><day>25</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>5</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>32</volume><issue>7</issue><fpage>1537</fpage><lpage>1538</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</uri>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri xlink:href="dex208.pdf"/><related-article id="d35e204" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1093/humrep/deu139"/><counts><page-count count="2"/></counts></article-meta></front><body><p>
<italic>Hum Reprod</italic> 2017;<bold>32</bold>:544&#x02013;555</p><p>The authors would like to apologize for an error in Table I of the above manuscript, describing the ESHRE Bologna criteria. Table I was originally based on <xref rid="dex208C2" ref-type="bibr">Ferraretti and Gianaroli, 2014</xref> rather than the original Bologna criteria article (<xref rid="dex208C1" ref-type="bibr">Ferraretti <italic>et al</italic>., 2011</xref>). Ferraretti and Gianaroli states that cancelled cycles should be included in the determination of previous episodes of poor ovarian response (POR). Although the use of cancelled cycles had been discussed for inclusion as a criterion to identify previous episodes of POR, this was not included in the final 2011 consensus. A revised version of Table <xref ref-type="table" rid="dex208TB1">I</xref> can be found below.
<table-wrap id="dex208TB1" orientation="portrait" position="float"><label>Table I</label><caption><p>The ESHRE Bologna criteria and the ESPART trial inclusion criteria for POR.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">2011 ESHRE Bologna criteria, <xref rid="dex208C1" ref-type="bibr">Ferraretti <italic>et al</italic>. (2011)</xref></th><th align="left" rowspan="1" colspan="1">ESPART POR inclusion criteria<sup>*</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Advanced maternal age (&#x02265;40 years) or any other risk factor</td><td rowspan="1" colspan="1">Advanced maternal age (&#x02265;40&#x02013;&#x0003c;41 years, i.e. patients between their 40<sup>th</sup> and 41<sup>st</sup> birthday)</td></tr><tr><td rowspan="1" colspan="1">A previous POR (&#x02264;3 oocytes with a conventional stimulation protocol)</td><td rowspan="1" colspan="1">Previous ART cycle with &#x02264;3 oocytes retrieved with a conventional stimulation protocol</td></tr><tr><td rowspan="1" colspan="1">An abnormal ORT (AFC&#x000a0;&#x0003c;5&#x02013;7 follicles or AMH&#x000a0;&#x0003c;0.5&#x02013;1.1 ng/ml)</td><td rowspan="1" colspan="1">An abnormal ORT (AMH 0.12&#x02013;1.3 ng/ml; measured by AMH GEN II ELISA, Beckman Coulter, Inc., High Wycombe, UK) <xref rid="dex208C3" ref-type="bibr">La Marca and Sunkara (2014)</xref></td></tr><tr><td rowspan="1" colspan="1">In the absence of advanced maternal age or abnormal ORT, two previous episodes of POR after maximal stimulation</td><td rowspan="1" colspan="1">Patients with two previous episodes of POR after maximal stimulation were excluded</td></tr></tbody></table><table-wrap-foot><fn id="dex208tfn1"><p>*Two out of three POR inclusion criteria needed to be met for inclusion in the ESPART trial.</p></fn><fn id="dex208tfn2"><p>AFC, antral follicle count; ORT, ovarian reserve test; POR, poor ovarian response; ESPART, Efficacy and Safety of Pergoveris in Assisted Reproductive Technology.</p></fn></table-wrap-foot></table-wrap></p><p>The authors would like to reassure readers that this does not affect any other content of the article.</p></body><back><ref-list><title>References</title><ref id="dex208C1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ferraretti</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>La Marca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fauser</surname><given-names>BCJM</given-names></name>, <name name-style="western"><surname>Tarlatzis</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nargund</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gianaroli</surname><given-names>L</given-names></name></person-group>
<article-title>ESHRE consensus on the definition of &#x02018;poor response&#x02019; to ovarian stimulation for in vitro fertilization: the Bologna criteria</article-title>. <source>Hum Reprod</source><year>2011</year>;<volume>26</volume>:<fpage>1616</fpage>&#x02013;<lpage>1624</lpage>.<pub-id pub-id-type="pmid">21505041</pub-id></mixed-citation></ref><ref id="dex208C2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ferraretti</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Gianaroli</surname><given-names>L</given-names></name></person-group>
<article-title>The Bologna criteria for the definition of poor ovarian responders: is there a need for revision</article-title>. <source>Hum Reprod</source><year>2014</year>;<volume>29</volume>:<fpage>1842</fpage>&#x02013;<lpage>1845</lpage>.<pub-id pub-id-type="pmid">25008235</pub-id></mixed-citation></ref><ref id="dex208C3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>La Marca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sunkara</surname><given-names>SK</given-names></name></person-group>
<article-title>Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice</article-title>. <source>Hum Reprod Update</source><year>2014</year>;<volume>20</volume>:<fpage>124</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">24077980</pub-id></mixed-citation></ref></ref-list></back></article>